Dry eye Disease (DED) effects up to 30% of the global population (2.25 Billion people) and thisinflammatory condition of ocular surfaceshas symptoms of visual disturbances, eye discomfort, tear film instability, etc.In the United States the average cost of treating this anomaly is over $6,500 with incidence rate of up to 20 million patients.This meeting will discuss three primary treatments of Cyclosporine 5%, Lifitegrast, and studies showing significance and differences between these treatments.
